Cargando…

Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration

We seek to demonstrate whether therapeutic efficacy can be improved by combination of repeated intravenous administration and local transplantation of human induced pluripotential stem cell derived MSCs (hiPSC-MSCs). In this study, mice model of hind-limb ischemia is established by ligation of left...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Si-Jia, Li, Fei, Dong, Ming, Liang, Wei-Hao, Lai, Wing-Hon, Ho, Wai-In, Wei, Rui, Huang, Yan, Liao, Song-Yan, Tse, Hung-Fat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411616/
https://www.ncbi.nlm.nih.gov/pubmed/36008710
http://dx.doi.org/10.1038/s42003-022-03833-8
_version_ 1784775308921012224
author Sun, Si-Jia
Li, Fei
Dong, Ming
Liang, Wei-Hao
Lai, Wing-Hon
Ho, Wai-In
Wei, Rui
Huang, Yan
Liao, Song-Yan
Tse, Hung-Fat
author_facet Sun, Si-Jia
Li, Fei
Dong, Ming
Liang, Wei-Hao
Lai, Wing-Hon
Ho, Wai-In
Wei, Rui
Huang, Yan
Liao, Song-Yan
Tse, Hung-Fat
author_sort Sun, Si-Jia
collection PubMed
description We seek to demonstrate whether therapeutic efficacy can be improved by combination of repeated intravenous administration and local transplantation of human induced pluripotential stem cell derived MSCs (hiPSC-MSCs). In this study, mice model of hind-limb ischemia is established by ligation of left femoral artery. hiPSC-MSCs (5 × 10(5)) is intravenously administrated immediately after induction of hind limb ischemia with or without following intravenous administration of hiPSC-MSCs every week or every 3 days. Intramuscular transplantation of hiPSC-MSCs (3 × 10(6)) is performed one week after induction of hind-limb ischemia. We compare the therapeutic efficacy and cell survival of intramuscular transplantation of hiPSC-MSCs with or without a single or repeated intravenous administration of hiPSC-MSCs. Repeated intravenous administration of hiPSC-MSCs can increase splenic regulatory T cells (Tregs) activation, decrease splenic natural killer (NK) cells expression, promote the polarization of M2 macrophages in the ischemic area and improved blood perfusion in the ischemic limbs. The improved therapeutic efficacy of MSC-based therapy is due to both increased engraftment of intramuscular transplanted hiPSC-MSCs and intravenous infused hiPSC-MSCs. In conclusion, our study support a combination of repeated systemic infusion and local transplantation of hiPSC-MSCs for cardiovascular disease.
format Online
Article
Text
id pubmed-9411616
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94116162022-08-27 Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration Sun, Si-Jia Li, Fei Dong, Ming Liang, Wei-Hao Lai, Wing-Hon Ho, Wai-In Wei, Rui Huang, Yan Liao, Song-Yan Tse, Hung-Fat Commun Biol Article We seek to demonstrate whether therapeutic efficacy can be improved by combination of repeated intravenous administration and local transplantation of human induced pluripotential stem cell derived MSCs (hiPSC-MSCs). In this study, mice model of hind-limb ischemia is established by ligation of left femoral artery. hiPSC-MSCs (5 × 10(5)) is intravenously administrated immediately after induction of hind limb ischemia with or without following intravenous administration of hiPSC-MSCs every week or every 3 days. Intramuscular transplantation of hiPSC-MSCs (3 × 10(6)) is performed one week after induction of hind-limb ischemia. We compare the therapeutic efficacy and cell survival of intramuscular transplantation of hiPSC-MSCs with or without a single or repeated intravenous administration of hiPSC-MSCs. Repeated intravenous administration of hiPSC-MSCs can increase splenic regulatory T cells (Tregs) activation, decrease splenic natural killer (NK) cells expression, promote the polarization of M2 macrophages in the ischemic area and improved blood perfusion in the ischemic limbs. The improved therapeutic efficacy of MSC-based therapy is due to both increased engraftment of intramuscular transplanted hiPSC-MSCs and intravenous infused hiPSC-MSCs. In conclusion, our study support a combination of repeated systemic infusion and local transplantation of hiPSC-MSCs for cardiovascular disease. Nature Publishing Group UK 2022-08-25 /pmc/articles/PMC9411616/ /pubmed/36008710 http://dx.doi.org/10.1038/s42003-022-03833-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Sun, Si-Jia
Li, Fei
Dong, Ming
Liang, Wei-Hao
Lai, Wing-Hon
Ho, Wai-In
Wei, Rui
Huang, Yan
Liao, Song-Yan
Tse, Hung-Fat
Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration
title Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration
title_full Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration
title_fullStr Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration
title_full_unstemmed Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration
title_short Repeated intravenous administration of hiPSC-MSCs enhance the efficacy of cell-based therapy in tissue regeneration
title_sort repeated intravenous administration of hipsc-mscs enhance the efficacy of cell-based therapy in tissue regeneration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9411616/
https://www.ncbi.nlm.nih.gov/pubmed/36008710
http://dx.doi.org/10.1038/s42003-022-03833-8
work_keys_str_mv AT sunsijia repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT lifei repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT dongming repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT liangweihao repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT laiwinghon repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT howaiin repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT weirui repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT huangyan repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT liaosongyan repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration
AT tsehungfat repeatedintravenousadministrationofhipscmscsenhancetheefficacyofcellbasedtherapyintissueregeneration